We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi, Regeneron to Appeal Injunction Barring the Sales of Cholesterol Drug in U.S.
Sanofi, Regeneron to Appeal Injunction Barring the Sales of Cholesterol Drug in U.S.
Sanofi and Regeneron intend to appeal a federal court injunction banning the sale of their cholesterol drug Praluent after a judge found the companies infringed an Amgen patent covering its Repatha.